WO2008153150A1 - Method for culturing cell population containing nk cells and use of the cell population - Google Patents

Method for culturing cell population containing nk cells and use of the cell population Download PDF

Info

Publication number
WO2008153150A1
WO2008153150A1 PCT/JP2008/060900 JP2008060900W WO2008153150A1 WO 2008153150 A1 WO2008153150 A1 WO 2008153150A1 JP 2008060900 W JP2008060900 W JP 2008060900W WO 2008153150 A1 WO2008153150 A1 WO 2008153150A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell population
monoclonal antibody
therapeutic agent
effect
Prior art date
Application number
PCT/JP2008/060900
Other languages
French (fr)
Japanese (ja)
Inventor
Shiho Sato
Hidemasa Jinguji
Atsutaka Noguchi
Masato Muto
Takamichi Izumi
Original Assignee
Medinet Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co., Ltd. filed Critical Medinet Co., Ltd.
Publication of WO2008153150A1 publication Critical patent/WO2008153150A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

It is intended to provide a method for efficiently proliferating and activating a cell population containing a high percentage of NK cells and γδT cells. Further, it is also intended to provide a pharmaceutical and a therapeutic method in which the cell population and a monoclonal antibody therapeutic agent are used in combination for enhancing an effect of the monoclonal antibody therapeutic agent via ADCC. By adding glucocorticoid and IL-18 to peripheral blood mononuclear cells after initiation of culture, NK cells and γδT cells can be selectively proliferated, and a cell population containing a large amount of NK cells and γδT cells with a high growth rate can be obtained. The obtained cell population has an excellent cytotoxic activity and cell preservation stability. Further, the ratio of CD16-positive cells is high, therefore, an effect of enhancing ADCC is high. Accordingly, the NK cells can increase a therapeutic effect of a monoclonal antibody therapeutic agent via ADCC.
PCT/JP2008/060900 2007-06-15 2008-06-13 Method for culturing cell population containing nk cells and use of the cell population WO2008153150A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007159578A JP2010220479A (en) 2007-06-15 2007-06-15 Method for culturing nk cell and use of the same
JP2007-159578 2007-06-15

Publications (1)

Publication Number Publication Date
WO2008153150A1 true WO2008153150A1 (en) 2008-12-18

Family

ID=40129753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060900 WO2008153150A1 (en) 2007-06-15 2008-06-13 Method for culturing cell population containing nk cells and use of the cell population

Country Status (2)

Country Link
JP (1) JP2010220479A (en)
WO (1) WO2008153150A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176796A1 (en) * 2011-06-24 2012-12-27 国立大学法人九州大学 Method for amplifying nk cells
JP2013006793A (en) * 2011-06-24 2013-01-10 Tella Inc Composition and method for amplifying nk cell
CN111748524A (en) * 2020-05-08 2020-10-09 嘉禾弘生(深圳)健康产业集团有限公司 Method for efficiently amplifying NK cells in vitro by using factor method
CN112912494A (en) * 2018-07-26 2021-06-04 耶稣圣婴儿童医院 Therapeutic formulations of gamma-delta T cells and natural killer cells and methods of making and using
CN113398262A (en) * 2021-06-18 2021-09-17 北京康爱瑞浩生物科技股份有限公司 Composition for treating HER2 positive gastric cancer and application

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101909879B1 (en) * 2015-06-24 2018-10-19 주식회사 차바이오텍 Method and Composition for Proliferating of Natural Killer Cell
WO2016209021A1 (en) * 2015-06-24 2016-12-29 주식회사 차바이오텍 Method for proliferating natural killer cells and composition for proliferating natural killer cells
JP6073417B2 (en) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド Spontaneous killing cell proliferation method and composition for spontaneous killing cell proliferation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOWLES J.A. ET AL.: "CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells", J. IMMUNOL. METHODS, vol. 304, no. 1-2, 2005, pages 88 - 99, XP005065140 *
HASHIMOTO W. ET AL.: "Interleukin-18(IL-18) ni yoru Natural Killer(NK) Saibo Kasseika Oyobi Shuyo Saibo no Apoptosis Yudo", TOKEIBU SYUYO, vol. 29, no. 1, 25 March 2003 (2003-03-25), pages 217 - 223 *
HASHIMOTO W. ET AL.: "Interleukin-18(IL-18) ni yoru Natural Killer(NK) Saibo Kasseika Oyobi Shuyo Saibo no Apoptosis Yudo; Tokeibu Shuyo Chiryo eno Oyo", TOHOKU UNIVERSITY DENTAL JOURNAL, vol. 22, no. 2, 30 December 2003 (2003-12-30), pages 124 - 125 *
ISHIDA T. ET AL.: "Gan Men'eki no Shin Tenkai Kotai Ryoho no Saranaru Tenkai", GEKKAN MEDICAL SCIENCE DIGEST, vol. 30, no. 4, 25 April 2004 (2004-04-25), pages 138 - 142 *
KITAMURA M. ET AL.: "Bunshi Hyoteki Chiryoyaku -Atarashii Gan Chiryoyaku-", JIBIINKOKA TENBO, vol. 47, no. 6, 15 December 2004 (2004-12-15), pages 455 - 459 *
YOSHITAKE Y. ET AL.: "Gan Men'eki Ryoho Kenkyu no Shin Tenkai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 63, no. 4, 28 April 2005 (2005-04-28), pages 46 - 55 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176796A1 (en) * 2011-06-24 2012-12-27 国立大学法人九州大学 Method for amplifying nk cells
JP2013006793A (en) * 2011-06-24 2013-01-10 Tella Inc Composition and method for amplifying nk cell
JP2013027385A (en) * 2011-06-24 2013-02-07 Kyushu Univ Method for amplifying nk cells
CN103620022A (en) * 2011-06-24 2014-03-05 国立大学法人九州大学 Method for amplifying nk cells
CN103620022B (en) * 2011-06-24 2015-09-30 国立大学法人九州大学 The amplification method of NK cell
US9404083B2 (en) 2011-06-24 2016-08-02 Kyushu University, National University Corporation Method for amplifying NK cells
CN112912494A (en) * 2018-07-26 2021-06-04 耶稣圣婴儿童医院 Therapeutic formulations of gamma-delta T cells and natural killer cells and methods of making and using
JP2021532829A (en) * 2018-07-26 2021-12-02 オスペダーレ ペディアトリコ バンビーノ ジェズ Therapeutic preparations and methods of manufacture and use of gamma-delta T cells and natural killer cells
JP7565271B2 (en) 2018-07-26 2024-10-10 オスペダーレ ペディアトリコ バンビーノ ジェズ Therapeutic preparations of gamma-delta T cells and natural killer cells and methods of making and using
CN111748524A (en) * 2020-05-08 2020-10-09 嘉禾弘生(深圳)健康产业集团有限公司 Method for efficiently amplifying NK cells in vitro by using factor method
CN113398262A (en) * 2021-06-18 2021-09-17 北京康爱瑞浩生物科技股份有限公司 Composition for treating HER2 positive gastric cancer and application

Also Published As

Publication number Publication date
JP2010220479A (en) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2008153150A1 (en) Method for culturing cell population containing nk cells and use of the cell population
NZ609201A (en) Means and methods for treating dlbcl
WO2011150055A3 (en) Methods, substrates, and systems useful for cell seeding of medical grafts
WO2012030057A3 (en) Medium composition for culturing self-activated lymphocytes and method for culturing self-activated lymphocytes using same
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
AU2012274478A8 (en) Method for amplifying NK cells
WO2008136398A1 (en) Cell culture method using amino acid-enriched medium
MY156588A (en) Systems using cell culture for production of isoprene
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
JP2015061520A5 (en)
MX2010002426A (en) Agent for promoting corneal endothelial cell adhesion.
IN2015DN01737A (en)
EP2588594A4 (en) Methods for culturing undifferentiated cells using sustained release compositions
WO2008090826A1 (en) Method for production of mesenchymal cell, method for production of tooth, and mesenchymal cell for formation of tooth
WO2009145419A9 (en) Composition comprising vegetable peptone for promoting stem cell proliferation
RU2006146795A (en) COMPOSITION FOR STIMULATING GROWTH AND REGENERATION OF CELLS, AND ALSO WAYS OF ITS OBTAINING
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
WO2012131733A3 (en) Media compositions for enriching cultures of stem cells
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
JP2012143229A5 (en)
WO2009016078A3 (en) Method for culturing mammalian stem cells
WO2011099783A3 (en) Method for producing cell growth factors from adipose-derived stem cells and monocytes and applications thereof
MX2013006838A (en) Effervescent compositions and uses thereof.
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
WO2009060865A1 (en) Pharmaceutical composition and method for production of pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP